Oncodesign Precision Medicine SA

10/22/2026 | Press release | Distributed by Public on 10/22/2026 10:11

OPM announces its 2026 half-year financial results and provides an update on its clinical developments and financial position

OPM announces its 2026 half-year financial results and provides an update on its clinical developments and financial position

Dijon, France, October 22, 2026, 6:00 p.m. CEST - Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its financial results for the first half of 2026, ended June 30, 2026.

Oncodesign Precision Medicine SA published this content on October 22, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 22, 2026 at 16:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]